The iPLEDGE program is a set of steps that all patients, prescribers, and pharmacists must follow prior to dispensing:

Dofetilide is a medication used to treat irregular heartbeats, specifically atrial fibrillation. It does not fall under the purview of the iPLEDGE program, as its usage and associated risks do not align with the objectives of the isotretinoin-focused program.

Clozapine is an antipsychotic medication primarily indicated for the treatment of schizophrenia in cases where other antipsychotics have been ineffective. The dispensing of clozapine does not require adherence to the iPLEDGE program protocols, as it serves a different medical purpose unrelated to acne treatment.

Thalidomide is a medication with multiple uses, including the treatment of certain cancers like multiple myeloma and complications of leprosy. However, it is not subject to the regulations and monitoring of the iPLEDGE program, which is specifically tailored for isotretinoin dispensing.